Dr. Ying Huang 黄莹
Chief Physician
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for head and neck tumors, including nasopharyngeal, nasal cavity, sinus, laryngeal, tongue, oropharyngeal, hypopharyngeal, oral, and gingival cancers. Also treats orbital malignancies, lymphoma, ocular inflammatory pseudotumor, and skin keloids.
Dr. Huang is a Chief Physician at Sun Yat-sen University Cancer Center. Clinical focus includes radiation therapy for malignant head and neck tumors, particularly nasopharyngeal cancer.
Professional roles
- Member, Chinese Medical Association
- Youth Committee Member, Nasopharyngeal Cancer Professional Committee, China Anti-Cancer Association
- Member and Secretary-General, Radiotherapy Professional Committee, Guangdong Anti-Cancer Association
- Vice Chair, Youth Committee, Radiotherapy Professional Committee, Guangdong Anti-Cancer Association
Name order: in Chinese the family name comes first (Huang Ying). Papers usually list the name as Ying Huang or Huang Y.
Selected publications
71 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Cell Mol Med, 2026 (senior author): PLOD1 Drives Head and Neck Squamous Cell Carcinoma Progression Through P4HA2-Mediated Activation of the FAK/PI3K/AKT/mTOR Axis. PubMed 42400233
- Transl Oncol, 2025 (first author): ZNF37A downregulation promotes TNFRSF6B expression and leads to therapeutic resistance to concurrent chemoradiotherapy in rectal cancer patients. PubMed 39571490
- Adv Sci (Weinh), 2024 (first author): Calcium Peroxide-Based Hydrogels Enable Biphasic Release of Hydrogen Peroxide for Infected Wound Healing. PubMed 39225304
- Clin Transl Oncol, 2024 (senior author): Correction: Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first‑line immunochemotherapy. PubMed 38416316
- Clin Transl Oncol, 2024 (senior author): Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first-line immunochemotherapy. PubMed 38070050
- Radiother Oncol, 2023 (senior author): The role of postoperative radiotherapy (PORT) in lymphoepithelial carcinoma of the salivary gland (LECSG) and the effect of postoperative EBV DNA on prognosis. PubMed 37659661
- Cancer Med, 2023 (senior author): Risk stratification and beneficiary selection among elderly nasopharyngeal carcinoma patients from concurrent chemoradiotherapy combined with induction chemotherapy. PubMed 37062057
- Front Oncol, 2021 (senior author): Efficacy and Toxicity of Three Induction Chemotherapy Regimens in Locoregionally Advanced Nasopharyngeal Carcinoma: Outcomes of 10-Year Follow-Up. PubMed 34722320
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion